Page last updated: 2024-08-23

heme and Diabetic Neuropathies

heme has been researched along with Diabetic Neuropathies in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Edmundson, S; Gurieva, I; Mankovsky, B; Papanas, N; Strokov, I; Ziegler, D	1
Abylaiuly, Z; Gurieva, I; Mankovsky, B; Movsesyan, L; Strokov, I; Ziegler, D	1
Andriambeloson, E; Dieckmann, A; Elmlinger, M; Kriebel, M; Ziegler, D	1

Trials

2 trial(s) available for heme and Diabetic Neuropathies

Article	Year
Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. Journal of diabetes and its complications, 2017, Volume: 31, Issue:7 Topics: Administration, Oral; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Central Nervous System Stimulants; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Resistance; Female; Heme; Humans; Infusions, Intravenous; Intention to Treat Analysis; Male; Models, Neurological; Pain; Peripheral Nervous System Diseases; Polyneuropathies; Severity of Illness Index; Tablets	2017
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes care, 2009, Volume: 32, Issue:8 Topics: Administration, Oral; Blood Pressure; Body Mass Index; Central Nervous System Stimulants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Female; Heart Rate; Heme; Humans; Infusions, Intravenous; Male; Mental Health; Middle Aged; Placebos; Treatment Outcome	2009

Article

Year

Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy.

Journal of diabetes and its complications, 2017, Volume: 31, Issue:7

Topics: Administration, Oral; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Central Nervous System Stimulants; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Resistance; Female; Heme; Humans; Infusions, Intravenous; Intention to Treat Analysis; Male; Models, Neurological; Pain; Peripheral Nervous System Diseases; Polyneuropathies; Severity of Illness Index; Tablets

2017

Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Diabetes care, 2009, Volume: 32, Issue:8

Topics: Administration, Oral; Blood Pressure; Body Mass Index; Central Nervous System Stimulants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Female; Heart Rate; Heme; Humans; Infusions, Intravenous; Male; Mental Health; Middle Aged; Placebos; Treatment Outcome

2009

Other Studies

1 other study(ies) available for heme and Diabetic Neuropathies

Article	Year
Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2012, Volume: 120, Issue:3 Topics: Animals; Central Nervous System Stimulants; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Evaluation, Preclinical; Enzyme Inhibitors; Heme; Male; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Signal Transduction; Streptozocin	2012

Article

Year

Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2012, Volume: 120, Issue:3

Topics: Animals; Central Nervous System Stimulants; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Evaluation, Preclinical; Enzyme Inhibitors; Heme; Male; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Signal Transduction; Streptozocin

2012